Västra Hamnen Corp. Finance

• Focus on out-licensing CG01 again

• Promising development in the COZY programme

• We initiate coverage with a fair value of SEK 12.19 per share

The prospects for gene therapies have raised the hopes and expectations of patients, healthcare professionals and investors in the life sciences industry. The first therapies have been approved, and more are on the way. Gene therapies are expected to take off in the 2020s as global pharmaceutical companies compete to position themselves in a field with great medical and commercial potential. Swedish gene therapy specialist CombiGene focuses on discovering promising projects, developing them into the clinical phase and out-licensing them after achieving preclinical proof of concept.

Västra Hamnen initiates research coverage of CombiGene with a fair value of SEK 12.19 per share. The full report is available here.